Open-label, Multicenter, Non-Comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) or Compensated Liver Cirrhosis in Real Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C; Liver cirrhosis
- Focus Therapeutic Use
- Acronyms STANDART
- Sponsors Roche
- 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 01 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.